Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
Parakkal Deepak, Edward V Loftus Jr Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA Abstract: Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway h...
Main Authors: | Deepak P, Loftus EV Jr |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-11-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/ustekinumab--in-treatment-of-crohnrsquos-disease-design-development-an-peer-reviewed-article-DDDT |
Similar Items
-
Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
by: Jauregui-Amezaga A, et al.
Published: (2017-11-01) -
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
by: Toshifumi Hibi, et al.
Published: (2017-10-01) -
Clinical utility of ustekinumab in Crohn’s disease
by: Kotze PG, et al.
Published: (2018-02-01) -
All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective
by: Jefremow A, et al.
Published: (2020-11-01) -
Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature
by: C. Venturin, et al.
Published: (2017-06-01)